1Dunaif AE. Insulin resistance and the polycystic ovary syndrome :Mechanism and implications for pathogenesis[ J ]. Endocr Rev, 1997,18(6) :744-800.
2Goudos VT, Dumesic DA. Polycystic ovary syndrome [ J ]. Endocrinol Metab Clin North Am, 1997,26(4):893-912.
3Pugeat M, Crave JC, Toumiaire J, et al. Clinical utility of sex hormone-binding globulin measurement [ J ]. Horm Res, 1996, 45 ( 3-5 ) : 148-155.
4Qin KN, Rosenfield RL. Role of cytochrome P450c17 in polycystic ovary syndrom[ J ]. Mol cell Endocrinol, 1998,145 (1-2) : 111-121.
5Taketani Y, Mizuno M. A syndrome of hyperandrogenism. Insulin resistance, and acanthosis nigricans associated with polycystic ovary syndrome: clinical and laboratory features [ J ]. Horm Res, 1990,33 [ Suppl 2] :27.
6Holte J. Polycystic ovary syndrome and insulin resistance ;thrifty genes struggling with overfeeding and sedentary life[J] ? J Endocrinol Invest,1998,21(9) :589-601.
7Dunaif A. Hyperandrogenic anovulation (PCOS) : a unique disorder of insulin associated with an increased risk of non- insulin dependent diabetes mellitus[ J] .Am J Med, 1995,98(1A):33s-39s.
8Nestler JE, Jakubowiez DJ. Decreases in ovarian eytechrome P450c17 alpha activity and serum free testosterone after reduction of insulin secretion in polycystic ovary syndrom[J]. Med, 1996,335(9):617.
9Velazquez E, Acosta A, Mendoza SG, et al. Menstrural Cyslicity After Metformin Therapy In Polycystic Ovary Syndrome[J]. Obstet Gynecol,1997,90(3) :392-395.
10De Leo V, Lamarca A, Qrvieto R, et al. Effection of Metformin on Insulin-like Growth Fator (IGF) and IGF-binding Protein 1 In polycystic Ovary Syndrom [ J ]. J Clin Endocrinol Metab, 2000, 85 ( 4 ) : 1598-16OO.
